Scarica l'app Stockscreener
0.37
5.41%
0.019
Precedente Chiudi:
$0.351
Aprire:
$0.359
Volume 24 ore:
14,367
Relative Volume:
0.12
Capitalizzazione di mercato:
$14.95M
Reddito:
$7.88M
Utile/perdita netta:
$-69.20M
Rapporto P/E:
-0.2022
EPS:
-1.83
Flusso di cassa netto:
$-69.73M
1 W Prestazione:
-5.13%
1M Prestazione:
-7.73%
6M Prestazione:
-43.81%
1 anno Prestazione:
-66.36%
Intervallo 1D:
$0.3506
$0.37
Intervallo di 1 settimana:
$0.3407
$0.4048
Portata 52W:
$0.30
$1.335
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Nome
Bolt Biotherapeutics Inc
Settore
Industria
Telefono
650-665-9295
Indirizzo
900 CHESAPEAKE DRIVE, REDWOOD CITY
Confronta BOLT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
0.37 | 14.95M | 7.88M | -69.20M | -69.73M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.46 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
608.00 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
651.09 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
260.00 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
257.10 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | Iniziato | Guggenheim | Buy |
| 2021-03-02 | Iniziato | Morgan Stanley | Overweight |
| 2021-03-02 | Iniziato | SVB Leerink | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
Bolt Biotherapeutics Inc Borsa (BOLT) Ultime notizie
Bolt Biotherapeutics amends bylaws, adjusts quorum requirement - Investing.com Australia
Innovative Advances in Bolt Biotherapeutics (BOLT) Cancer Therap - GuruFocus
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - The Manila Times
New Cancer Treatment Breakthrough: Bolt Bio's Dual-Target Therapy Achieves Complete Response in Early Tests - Stock Titan
Bolt Biotherapeutics amends bylaws, adjusts quorum requirement By Investing.com - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Esca - GuruFocus
Bolt Biotherapeutics reports positive Phase 1 cancer trial results By Investing.com - Investing.com India
Bolt Biotherapeutics Reports Positive Phase 1 Results for BDC-3042, Demonstrating Safety and Anti-Tumor Activity in Cancer Patients - Nasdaq
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - The Manila Times
Breakthrough Cancer Drug Achieves 80% Disease Control: Phase 1 Trial Reveals Promising NSCLC Results - Stock Titan
Bolt Biotherapeutics modifies quorum requirements By Investing.com - Investing.com Canada
Bolt Biotherapeutics modifies quorum requirements - Investing.com
BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - marketscreener.com
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Sept. 3rd Deadline ALERT: Investors Who Lost More Than $100,000 With Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shares Should Contact the Shareholders Foundation - ACCESS Newswire
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Bolt Biotherapeutics, Inc. (BOLT) - ACCESS Newswire
Bolt Biotherapeutics stock hits 52-week low at $0.38 By Investing.com - Investing.com UK
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
What is HC Wainwright’s Estimate for BOLT Q1 Earnings? - Defense World
What is Leerink Partnrs’ Forecast for BOLT Q1 Earnings? - Defense World
Q3 Earnings Forecast for BOLT Issued By HC Wainwright - Defense World
H.C. Wainwright holds Neutral on Bolt Biotherapeutics stock By Investing.com - Investing.com Australia
H.C. Wainwright holds Neutral on Bolt Biotherapeutics stock - Investing.com India
Bolt Biotherapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Bolt Biotherapeutics Inc (BOLT) Q4 2024 Earnings: EPS Misses at -$0.42, Revenue Falls Short at $0 Million - GuruFocus
Bolt Biotherapeutics’ (BOLT) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Bolt Biotherapeutics (NASDAQ:BOLT) Given New $1.25 Price Target at Stifel Nicolaus - Defense World
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - The Manila Times
Groundbreaking Cancer Drug Trial Results: First-Ever Dectin-2 Agonist Data Revealed at AACR 2025 - Stock Titan
Stifel cuts Bolt Biotherapeutics stock price target to $1.25 By Investing.com - Investing.com Australia
Stifel cuts Bolt Biotherapeutics stock price target to $1.25 - Investing.com
Bolt Biotherapeutics Reports 2024 Financial Results and Updates - TipRanks
Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot - The Washington Post
Bolt Biotherapeutics Updates on Clinical Trials and Financial Results, Anticipates Milestones for BDC-4182 and BDC-3042 - Nasdaq
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - The Manila Times
BOLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bolt Biotherapeutics stock hits 52-week low at $0.4 By Investing.com - Investing.com Australia
Bolt Biotherapeutics stock hits 52-week low at $0.4 - Investing.com India
Bolt Biotherapeutics (BOLT) to Release Earnings on Thursday - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.42 By Investing.com - Investing.com Australia
Bolt Biotherapeutics stock hits 52-week low at $0.42 - Investing.com India
Bolt Biotherapeutics Inc Azioni (BOLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.01%
2.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):